Alkermes plc (NASDAQ:ALKS) : Traders are bullish on Alkermes plc (NASDAQ:ALKS) as it has outperformed the S&P 500 by a wide margin of 12.95% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.17%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.54% in the last 1 week, and is up 14.77% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -24.75% from its 1 Year high price. On Dec 29, 2015, the shares registered one year high at $80.71 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $44.04 and the 200 Day Moving Average price is recorded at $42.58.
The stock has recorded a 20-day Moving Average of 13.38% and the 50-Day Moving Average is 15.74%.
Alkermes plc (NASDAQ:ALKS): stock turned positive on Friday. Though the stock opened at $47.77, the bulls momentum made the stock top out at $49.17 level for the day. The stock recorded a low of $47.01 and closed the trading day at $48.95, in the green by 1.89%. The total traded volume for the day was 924,911. The stock had closed at $48.04 in the previous days trading.
In an insider trading activity, Mitchell Paul J, director of Alkermes Plc., unloaded 2,000 shares at an average price of $45.81 on July 5, 2016. The total amount of the transaction was worth $91,620, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.